- Oops!Something went wrong.Please try again later.
Investors focused on the Medical space have likely heard of Celldex Therapeutics, Inc. (CLDX), but is the stock performing well in comparison to the rest of its sector peers? Let's take a closer look at the stock's year-to-date performance to find out.
Celldex Therapeutics, Inc. is one of 892 individual stocks in the Medical sector. Collectively, these companies sit at #1 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. CLDX is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for CLDX's full-year earnings has moved 12.54% higher. This is a sign of improving analyst sentiment and a positive earnings outlook trend.
Based on the most recent data, CLDX has returned 6.73% so far this year. Meanwhile, stocks in the Medical group have lost about 3.01% on average. This shows that Celldex Therapeutics, Inc. is outperforming its peers so far this year.
To break things down more, CLDX belongs to the Medical - Biomedical and Genetics industry, a group that includes 382 individual companies and currently sits at #16 in the Zacks Industry Rank. Stocks in this group have gained about 3.89% so far this year, so CLDX is performing better this group in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track CLDX. The stock will be looking to continue its solid performance.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Celldex Therapeutics Inc (CLDX) : Free Stock Analysis Report
To read this article on Zacks.com click here.